Securities code: 002932 securities abbreviation: Wuhan Easy Diagnosis Biomedicine Co.Ltd(002932) Announcement No.: 2022-004
Wuhan Easy Diagnosis Biomedicine Co.Ltd(002932)
Stock trading abnormal fluctuation announcement
The company and all members of the board of directors guarantee that the content of information disclosure is true, accurate and complete without falsehood
False records, misleading statements or material omissions.
1、 Introduction to abnormal fluctuations in stock trading
The trading price of Wuhan Easy Diagnosis Biomedicine Co.Ltd(002932) (hereinafter referred to as “the company”) shares (securities code “002932”, securities abbreviation ” Wuhan Easy Diagnosis Biomedicine Co.Ltd(002932) “) has been trading for two consecutive trading days (January 13, 2022 and 2022)
On January 14), the cumulative deviation of the closing price increase exceeded 20%, in accordance with the trading rules of Shenzhen Stock Exchange
The relevant provisions belong to abnormal fluctuations in stock trading.
2、 Description of concerns and verification on important issues
In view of the abnormal fluctuation of the company’s shares, the company checked relevant matters and asked the company’s controlling shareholders
Shareholders and actual controllers, the relevant information is described as follows:
(I) the company has not found any recent public media reports that may or have had an impact on the trading price of the company’s shares
Unpublished material information that has a great impact;
(II) there has been no significant change in the company’s business situation and internal and external business environment recently;
(III) after verification, the company, the controlling shareholder and the actual controller have no information about the company that should be disclosed
Major events not disclosed or in the planning stage;
(IV) after verification, Xinyu chenheng investment partnership (Co., Ltd.) is the person acting in concert of the actual controller of the company
The partnership) reduced its holdings on January 11, 2022, January 12, 2022 and January 13, 2022
The company has 489280 shares, as follows:
1. Share reduction by shareholders
Proportion of shares reduced in the average price of shares reduced (yuan)
Name of shareholder reduction method total share capital of the company during the reduction period (shares)
Proportion of (%)
January 11, 2022 94.87 141100 0.13%
Xinyu chenheng centralized bidding on January 12, 2022 93.62 170180 0.16%
January 13, 2022 101.95 178000 0.17%
Total 489280 0.47%
Since the disclosure of the pre disclosure announcement on the share reduction plan of the concerted action person of the actual controller on November 23, 2021, Xinyu chenheng investment partnership (limited partnership) and Mr. Wang Rui, deputy general manager and Secretary of the board of directors of the company, have reduced 901280 shares of the company.
Except for the above changes in shares, the controlling shareholder and actual controller of the company did not buy or sell the company’s shares during the period of stock change;
(V) through self-examination, the information disclosed by the company in the early stage does not need to be corrected or supplemented;
(VI) through self-examination, the company has no other circumstances in violation of the provisions on fair information disclosure.
3、 Whether there is a description of information that should be disclosed but not disclosed
The board of directors of the company confirms that, in addition to the above matters, the company has no undisclosed matters or planning, negotiation, intention, agreement, etc. related to the matters that should be disclosed in accordance with the stock listing rules of Shenzhen Stock Exchange and other relevant provisions; The board of directors has not been informed that the company has undisclosed information that should be disclosed in accordance with the stock listing rules of Shenzhen Stock Exchange and other relevant provisions and has a great impact on the trading price of the company’s shares and their derivatives; There is no need to correct or supplement the information disclosed by the company in the early stage.
4、 Risk tips
1. Through self-examination, the company does not violate the fair disclosure of information.
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions;
2. At this stage, the company is in the period of preparing the periodic report. The company has disclosed the annual performance forecast for 2021 on January 5, 2022. It is expected that the net profit attributable to the shareholders of the listed company in 2021 will be RMB 130 million-150 million, an increase of 177.23% – 219.88% over the same period of the previous year. Prior to the disclosure of this announcement, the company’s undisclosed periodic performance information was not provided to a third party other than the accounting firm audited by the company; The specific financial data of the company in 2021 shall be subject to the annual report of the company in 2021. The company shall not amend the annual performance forecast for 2021.
3. The board of directors of the company solemnly reminds investors that the information disclosure media designated by the company are securities times, China Securities News and cninfo（ http://www.cn.info.com.cn. ）, all information disclosure of the company shall be subject to the announcement published in the above media. The company will conscientiously perform the obligation of information disclosure and do a good job of information disclosure in a timely manner in strict accordance with the provisions and requirements of relevant laws and regulations. Please invest rationally and pay attention to risks.
It is hereby announced.
Wuhan Easy Diagnosis Biomedicine Co.Ltd(002932) board of directors
January 17, 2022
